HIV Infections Clinical Trial
Official title:
Piloting a Smartphone App to Improve Treatment Adherence Among South African Adolescents Living With HIV
Verified date | April 2024 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall goal of this pilot randomized-controlled trial (RCT) is to pilot MASI (MAsakhane Siphucule Impilo Yethu; Xhosa for "Let's empower each other and improve our health"), an ART adherence-supporting smartphone app with 50 adolescents and young adults living with HIV to assess its feasibility and acceptability and to explore preliminary effects on ART adherence and social support.
Status | Completed |
Enrollment | 50 |
Est. completion date | April 2, 2024 |
Est. primary completion date | March 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 21 Years |
Eligibility | Inclusion Criteria: - Age >= 15 years and <= 21 years - Knows HIV status (Screened adolescents who do not know their HIV status will receive information on free voluntary HIV counseling and testing services) - Living with HIV - Has been prescribed medication to treat HIV - Not attending school for learners with special needs (e.g., School of Skills) - Has not repeated a grade in school more than once - Has a smartphone that can download apps - Feels comfortable using an app with content in English - No plan to move outside of Cape Town in the next six months - Has not previously participated in the MASI app testing phase of our study - Able to successfully install the MASI app on their smartphone Exclusion Criteria: - Failure to meet any of the inclusion criteria - Child dissent despite parent, legal guardian, caregiver informed consent |
Country | Name | City | State |
---|---|---|---|
South Africa | University of Cape Town | Cape Town |
Lead Sponsor | Collaborator |
---|---|
Duke University | Florida State University, National Institute of Mental Health (NIMH), University of Cape Town, University of North Carolina |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intervention feasibility: Number of days participants log in to the app as recorded by app backend paradata | Feasibility will be measured by the number days participants log in to the app as recorded by app backend paradata | 3 months, 6 months | |
Primary | Intervention feasibility: Total time participants spend using the app | Feasibility will be measured by the total time, in minutes, participants spend using app as recorded by app backend paradata. | 3 months, 6 months | |
Primary | Intervention feasibility: Number of days participants log medications using the app as recorded by app backend paradata | Feasibility will be measured by the number of days participants log medications in the app as recorded by app backend paradata. | 3 months, 6 months | |
Primary | Intervention acceptability: Composite score from adapted system usability scale | Acceptability will be measured by an average of participants' scores on an adapted version of the System Usability Scale (SUS), a scale giving a global view of subjective assessments of usability. Total possible range: 0 - 100. Higher score indicates higher usability and helpfulness (better outcome). Average SUS >68 (average for digital health apps) will be considered acceptable. | 3 months, 6 months | |
Secondary | Adherence to ART, as measured by 30-day recall of missed doses | Adherence to antiretroviral therapy will be measured using the participant's self-reported number of missed ART doses in the past 30 days. | 3 months | |
Secondary | Adherence to ART, as measured by 30-day recall of missed doses | Adherence to antiretroviral therapy will be measured using the participant's self-reported number of missed ART doses in the past 30 days. | 6 months | |
Secondary | Perceived social support and social isolation using adapted Medical Outcomes Study Social Support Survey (MOS-SS) | Perceived social social support will be measured using an adapted version of the Medical Outcomes Study Social Support Survey (MOS-SS), which measures four domains of social support: emotional/informational support, tangible support, affectionate support, and positive social interaction. Total possible range: 12 - 48. Higher score indicates higher social support (better outcome). | 3 months | |
Secondary | Perceived social support and social isolation using adapted Medical Outcomes Study Social Support Survey (MOS-SS) | Perceived social social support will be measured using an adapted version of the Medical Outcomes Study Social Support Survey (MOS-SS), which measures four domains of social support: emotional/informational support, tangible support, affectionate support, and positive social interaction. Total possible range: 12 - 48. Higher score indicates higher social support (better outcome). | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |